ESP-01 is under clinical development by Esperas Pharma and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect ESP-01’s likelihood of approval (LoA) and phase transition for Endometrial Cancer took place on 01 Apr 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 01 Apr 2022 increased ESP-01’s LoA and PTSR for Epithelial Ovarian Cancer, increased LoA and PTSR for Gastrointestinal Stromal Tumor (GIST), increased LoA and PTSR for Metastatic Colorectal Cancer, increased PTSR for Pancreatic Cancer, and increased PTSR for Soft Tissue Sarcoma.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ESP-01 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

ESP-01 overview

ESP-01 is under development for the treatment of solid tumours including metastatic colorectal cancer, epithelial ovarian cancer, endometrial cancer, ewing sarcoma, soft tissue sarcoma, gastrointestinal stromal tumors (GIST), pancreatic cancer and triple-negative breast cancer (TNBC). It is administered by the oral route. The drug candidate acts by targeting checkpoint Kinase 1 (CHK 1).

Quick View ESP-01 LOA Data

Report Segments
  • Innovator
Drug Name
  • ESP-01
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.